Butyrate Restores Sleep in Parkinson’s Mice via BDNF

In a groundbreaking study published in npj Parkinson’s Disease in 2025, researchers have unveiled a novel therapeutic avenue for addressing sleep disturbances commonly associated with Parkinson’s disease (PD). The investigation, led by Duan, Xie, Ying, and colleagues, demonstrates that butyrate, a short-chain fatty acid known for its roles in gut health and neuroprotection, can significantly ameliorate abnormal sleep architecture in a Parkinson’s disease mouse model. This discovery pivots on the modulation of the brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling pathway, shedding light on complex biochemical underpinnings central to PD pathology and symptomatology. The significance of their findings resonates not only in the neuroscientific community but also in the broader context of neurodegenerative disease management.

Parkinson’s disease, predominantly recognized for its motor dysfunctions such as bradykinesia, rigidity, and resting tremor, is increasingly appreciated for its non-motor symptoms, notably sleep disturbances. These disruptions in sleep architecture, manifesting as fragmented sleep, rapid eye movement (REM) behavior disorder, and excessive daytime sleepiness, severely impair quality of life and exacerbate disease progression. The mechanisms driving these sleep abnormalities remain incompletely understood, but mounting evidence implicates neurochemical imbalances, neuronal loss in sleep-regulating brain regions, and impaired neurotrophic signaling. Duan and colleagues have thus focused on dissecting sleep-related neuropathology in PD, employing a rigorous mouse model that mimics both motor and non-motor deficits seen in human patients.

Central to the investigation is butyrate, a metabolite produced by gut microbiota through fermentation of dietary fibers. Butyrate’s role extends well beyond gut health, influencing systemic inflammation, epigenetic regulation, and neural function. In recent years, the gut-brain axis has emerged as critical in neurodegenerative diseases, with altered microbial composition and metabolite profiles linked to disease pathology. The administration of butyrate in the PD mouse model was hypothesized to exert neuroprotective effects, potentially normalizing disrupted signaling pathways and neuronal communication that underpin sleep disturbances. This study methodically tests this hypothesis, utilizing electrophysiological monitoring, molecular assays, and behavioral assessments to unravel butyrate’s influence on sleep and neurobiology.

.adsslot_A6Xkb9MD35{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_A6Xkb9MD35{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_A6Xkb9MD35{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Sleep architecture, referring to the cyclical pattern and stages of sleep including non-REM and REM phases, is critically disrupted in Parkinson’s disease. Abnormalities such as reduced REM sleep duration and altered slow-wave sleep impact synaptic plasticity and cognitive function. The study meticulously characterizes alterations in sleep stages in transgenic mice expressing PD-associated alpha-synuclein mutations, monitoring how butyrate administration restores these parameters. Findings reveal that butyrate significantly enhances REM and non-REM sleep integrity, normalizing disrupted rhythms, and reducing sleep fragmentation. These restorative effects suggest that butyrate corrects underlying neural circuit dysfunctions, offering a mollifying effect on PD-related sleep dysregulation.

At the molecular level, the focus converges on the BDNF/TrkB signaling axis, a crucial pathway for neuronal survival, synaptic plasticity, and neurogenesis. BDNF, abundantly expressed in the central nervous system, binds to the TrkB receptor to activate downstream cascades like the PI3K/Akt and MAPK/ERK pathways, promoting neuronal resilience and function. Parkinson’s pathology involves a decrease in BDNF levels and impaired TrkB signaling, contributing to neurodegeneration and functional deficits. The research team demonstrates that butyrate treatment elevates BDNF expression and enhances TrkB receptor activation in sleep-regulatory regions such as the hypothalamus and brainstem. This molecular reawakening is posited as the mechanistic basis for improved sleep architecture seen in PD mice.

Intriguingly, epigenetic modulation emerges as a key mechanism by which butyrate exerts its neuroprotective effects. Butyrate is a known histone deacetylase (HDAC) inhibitor, facilitating a more permissive chromatin state that enables transcription of neurotrophic genes including BDNF. The study reports an increase in histone acetylation marks within neural tissue following butyrate administration, correlating with elevated BDNF mRNA levels, suggesting transcriptional reprogramming underpinning restorative neural plasticity. This finding elegantly links metabolic signaling with gene expression regulation in PD pathology.

Beyond neuronal biochemical pathways, the research illuminates butyrate’s role in modulating neuroinflammation, a hallmark of Parkinson’s disease. Microglial activation and pro-inflammatory cytokine release exacerbate neuronal damage and are implicated in sleep disturbances. Butyrate treatment notably reduces markers of neuroinflammation, including decreased expression of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). This anti-inflammatory effect, likely synergistic with BDNF signaling enhancement, contributes to neuroprotection and functional normalization within sleep networks.

A particularly novel aspect of the study is its integration of gut microbiome dynamics with central nervous system health. Given butyrate’s microbial origin, the findings suggest the therapeutic modulation of gut microbiota could have profound implications for sleep and neurological health in PD. This supports an emerging paradigm where diet, microbiota, and their metabolites are seen as modulators of neurodegenerative disease progression and symptoms, potentially enabling non-invasive intervention strategies for managing PD-related sleep dysfunction.

The implications of this research extend significantly beyond the murine model. Sleep disturbances in Parkinson’s patients remain challenging to treat, often resistant to conventional pharmacotherapies and associated with increased morbidity. The discovery that butyrate or butyrate-enhancing interventions could restore sleep architecture opens promising therapeutic avenues. Potentially, dietary supplementation, prebiotics, probiotics, or pharmacological HDAC inhibitors targeting this pathway could become part of multifaceted PD management, improving not only motor symptoms but overall life quality.

Critically, the study employs advanced electrophysiological techniques including electroencephalogram (EEG) and electromyogram (EMG) recordings to quantify sleep stages with high fidelity. These objective measurements strengthen the validity of conclusions regarding sleep improvements, demonstrating that butyrate’s effects are not merely behavioral but rooted in normalized brain oscillatory activity. Future research could expand on these techniques to explore long-term impacts on cognitive function and neurodegeneration in PD.

Moreover, the precise delineation of BDNF/TrkB mediated pathways provides a molecular target for developing new classes of neuroprotective agents. Small molecules or biologics enhancing this signaling cascade might synergize with butyrate or mimic its effects, offering tailored strategies to curb neurotransmitter imbalances and neurodegeneration responsible for sleep and motor abnormalities. This could revolutionize PD treatment paradigms, shifting focus from symptomatic relief to underlying disease modification.

To summarize, the study by Duan and colleagues represents a major leap toward understanding and treating Parkinson’s disease-related sleep disturbances. Through a sophisticated blend of behavioral assays, molecular biology, epigenetics, and neurophysiology, it elucidates how butyrate rescues impaired sleep architecture by reactivating the BDNF/TrkB signaling axis and dampening neuroinflammation. This comprehensive approach underscores the multifactorial nature of PD symptoms and highlights the intertwined relationship between metabolism, genetics, and neurobiology.

As the global burden of Parkinson’s disease escalates with aging populations, such translational studies are paramount in guiding therapeutic innovation. While more work is needed to confirm efficacy and safety in human subjects, the current findings energize the field with hope that metabolic modulation via microbiota-derived metabolites could be harnessed effectively. The convergence of gut-brain research, neurotrophic factor biology, and epigenetics as presented in this work exemplifies cutting-edge neuroscience, with the potential to fundamentally alter how we perceive and treat neurodegenerative disease.

In conclusion, this research not only deepens our mechanistic understanding of sleep abnormalities in Parkinson’s disease but also unveils butyrate as a potent modulator with therapeutic promise. Through restoration of BDNF/TrkB signaling and suppression of inflammatory pathways, butyrate reestablishes healthy sleep patterns, offering a beacon of hope to millions afflicted by this devastating disorder. Future clinical trials inspired by these findings could pave the way for novel dietary or pharmacological interventions that improve both neural function and quality of life for Parkinson’s patients worldwide.

Subject of Research: Butyrate’s role in ameliorating sleep disturbances in Parkinson’s disease through modulation of BDNF/TrkB signaling in a mouse model.

Article Title: Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling

Article References:
Duan, WX., Xie, WY., Ying, C. et al. Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling. npj Parkinsons Dis. 11, 175 (2025). https://doi.org/10.1038/s41531-025-01029-5

Image Credits: AI Generated

Tags: BDNF signaling pathwaybutyrate and sleep disturbancesexcessive daytime sleepiness in Parkinson’sfragmented sleep and quality of lifemanaging neurodegenerative diseases.neurochemical imbalances in sleep disordersneuronal loss and sleep regulationneuroprotection and gut healthnon-motor symptoms of PDParkinson’s disease mouse modelsleep architecture in neurodegenerationtherapeutic avenues for Parkinson’s disease